SCULPTRA®

Sculptra **is the only FDA-approved poly-L-lactic acid (PLLA) facial injectable treatment that helps stimulate the skin's own natural collagen production. It works gradually to help restore your skin's inner structure to smooth facial wrinkles, such as smile lines, for a more youthful-looking appearance.[1-3]**

SUSTAINED RESULTS — UP TO 2 YEARS[3]*

**Clinical trial ended at 96 weeks (2 years).*

94%

94% of patients* agreed that the treatment results look natural at 2 years after last treatment[7†]

*Patients=clinical trial participants.

†8 mL SWFI + 1 mL 2% lidocaine immediate use *Sculptra* cohort (N=38) in a 96-week (2 years) extension clinical study with additional assessments at 6 months (24 weeks) and 1 year (48 weeks) after last treatment.

For more information about *Sculptra,* visit www.SculptraUSA.com

WHAT IS THE ROLE OF COLLAGEN IN AGING?

As we age, we lose collagen, which acts as the skin's support structure and helps maintain its shape.[4] In fact, 70% of our skin is composed of collagen,[5] and collagen loss causes the skin to lose its elasticity and moisture.[6]

Sculptra helps treat an underlying cause of facial aging—the loss of collagen.[3] By helping stimulate your own natural collagen growth, *Sculptra* gradually adds volume that lifts the soft tissues and plumps skin from within.[1-3]

WHAT TO EXPECT FROM YOUR *SCULPTRA* TREATMENT:

- **Stimulates** your own natural collagen growth
- **Helps restore lost facial volume and provides support** to the skin to improve the look of smile lines (nasolabial folds), marionette lines, preauricular wrinkles (the vertical wrinkles in front of the ears), radial cheek folds (vertical wrinkles below the cheek), and chin wrinkles[3]
- **Provides gradual and natural–looking results** that become visible over a few months[1-3]
- **Long-lasting**—lasts up to 2 years[3]*

**Individual results and treatment regimens may vary. Clinical trial ended at 96 weeks (2 years).*
The most common side effects after initial treatment include injection site swelling, tenderness, redness, pain, bruising, bleeding, itching and lumps. See full Important Safety Information on Page 2.

Before

After 27 Weeks

MARINA, 47

Actual patient. Individual results may vary. Treated with 3.8 vials over 3 sessions - 8mL reconstitution.

Before

After 16 Weeks

GEORGE, 50

Actual patient. Individual results may vary. Treated with 4 vials - 5 mL reconstitution

HOW DOES IT WORK?

Once injected *Sculptra* begins working with your body deep within the skin to help stimulate your skin's own natural collagen production over time, helping to reinforce the skin's inner structure and increase facial fullness that has been lost due to aging.[1-3]

HOW MANY TREATMENTS WILL I NEED?

On average, a series of 3 treatment sessions over the course of a few months may be needed. The number of injections at each session will vary depending on the degree of correction needed and the treatment plan determined by you and your specialist.

WHAT IS *SCULPTRA* MADE OF?

Sculptra is made from poly-L-lactic acid (PLLA), a biodegradable substance that has been proven safe and has been used in medical products, including dissolvable sutures, for more than 30 years.[8]

SCULPTRA®

TREATMENT PLAN

RECOMMENDED NUMBER OF VIALS:

NUMBER OF SESSIONS:

NEXT APPOINTMENT DATE:

IMPORTANT SAFETY INFORMATION

Indication: *Sculptra® (injectable poly-L-lactic acid)* is indicated for use in people with healthy immune systems for the correction of shallow to deep nasolabial fold contour deficiencies and other facial wrinkles.

Sculptra should not be used by people that are allergic to any ingredient of the product or have a history of keloid formation or hypertrophic scarring. Safety has not been established in patients who are pregnant, lactating, breastfeeding, or under 18 years of age.

Sculptra has unique injection requirements and should only be used by a trained healthcare practitioner. Contour deficiencies should not be overcorrected because they are expected to gradually improve after treatment.

Sculptra should not be injected into the blood vessels as it may cause vascular occlusion, infarction or embolic phenomena. Use at the site of skin sores, cysts, pimples, rashes, hives or infection should be postponed until healing is complete. *Sculptra* should not be injected into the red area (vermillion) of the lip or in the peri-orbital area.

The most common side effects after initial treatment include injection site swelling, tenderness, redness, pain, bruising, bleeding, itching and lumps. Other side effects may include small lumps under the skin that are sometimes noticeable when pressing on the treated area. Larger lumps, some with delayed onset with or without inflammation or skin discoloration, have also been reported.

Sculptra is available only through a licensed practitioner. Complete Instructions for Use are available at www.SculptraUSA.com/IFU.

REFERENCES:

1. Stein P, Vitavska O, Kind P, Hoppe W, Wieczorek H, Schürer NY. The biological basis for poly-L-lactic acid-induced augmentation. *J Dermatol Sci.* 2015;78:26-33. **2.** Goldberg D, Guana A, Volk A, Daro-Kaftan E. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. *Dermatol Surg.* 2013;39:915-922. **3.** *Sculptra.* Instructions for Use. Galderma Laboratories, L.P., 2021. **4.** Quan T, Wang F, Shao Y, et al. Enhancing structural support of the dermal microenvironment activates fibroblasts, endothelial cells, and keratinocytes in aged human skin in vivo. *J Invest Dermatol.* 2013 Mar;133(3):658-667. **5.** Ackerman AB, Boer A, Bennin B, et al. Embryologic, histologic, and anatomic aspects: collagen. In: *Histologic Diagnosis of Inflammatory Skin Diseases.* Third ed. 2005. https://www.derm101.com/inflammatory/embryologic-histologic-and-anatomic-aspects/collagen. Accessed May 30, 2018. **6.** Vleggaar D, Fitzgerald R. Dermatological implications of skeletal aging: a focus on supraperiosteal volumization for perioral rejuvenation. *J Drugs Dermatol.* 2008;7(3):209-220. **7.** Data on file. 43USSA1705ext clinical study report. Fort Worth, TX: Galderma Laboratories, L.P. 2021. **8.** Lowe NJ. Dispelling the myth: appropriate use of poly-L-lactic acid and clinical considerations. *J Eur Acad Dermatol Venereol*. 2006:20(1):2-6.

GALDERMA
EST. 1981